SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond.

Authors

Katherine Tuttle, Providence Medical Research Center, Providence Health Care, Spokane, WA 99204, USAFollow

Document Type

Article

Publication Date

1-1-2021

Publication Title

Lancet Diabetes Endocrinol

Keywords

Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2

Clinical Institute

Kidney & Diabetes

Department

Endocrinology

Recommended Citation

Tuttle, Katherine, "SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond." (2021). Articles, Abstracts, and Reports. 4243.
https://digitalcommons.providence.org/publications/4243